1. A Cancer Chemo-Prevention Compromise
In trials of cancer treatment or of "adjuvant therapies" (secondary prevention), subjects either have a diagnosis of cancer or a significant chance of disease relapse (Bedard 1). ... Now knowing the low baseline risk of breast cancer among trial participants, one can feel that IRBs should truly focus more on the magnitude of change in disease rates among the population when calculating prospective benefits and risks connected with investigational chemo-prevention agents. ... Both remedies were found to diminish the threat of emergent intrusive breast cancer by about 50%, but women wh...
- Word Count: 1354
- Approx Pages: 5
- Has Bibliography
- Grade Level: Graduate